女性の健康治療市場：タイプ別、流通チャネル別-2025～2030年の世界予測

女性の健康治療市場の2023年の市場規模は654億9,000万米ドルで、2024年には722億1,000万米ドルに達すると予測され、CAGR 10.74％で成長し、2030年には1,338億2,000万米ドルに達すると予測されています。

女性の健康治療市場は、生殖に関する健康、更年期障害、骨粗鬆症、特定の自己免疫疾患や心血管疾患など、女性特有の、あるいは女性に多く見られる症状や疾患に対処する治療に焦点を当てています。この市場の必要性は、女性特有の生理的ニーズにあり、女性特有の生物学的構造に合わせたより良い健康結果を保証します。市場内の用途には、医薬品、生物製剤、機器、診断薬が含まれ、最終用途には病院、クリニック、小売薬局、オンラインプラットフォームが含まれます。主要成長促進要因は、女性の健康問題に対する意識の高まり、医療支出の増加、バイオテクノロジーの進歩、女性の健康への取り組みを促進する政府の支援ポリシーなどです。個別化医療や、個別化されたモニタリングと治療を提供するウェアラブル端末や遠隔医療のようなデジタルヘルス技術の統合には機会があふれています。企業は、研究開発への投資や、ハイテク企業、医療プロバイダー、健康擁護団体との提携によって、こうした機会を活用することができます。しかし、市場成長は、高い調査費用、規制上の障壁、特定の地域における女性特有の健康問題をめぐる文化的偏見といった課題に直面しており、市場の浸透と受容の両方に影響を与えています。さらに、地域によっては償還ポリシーや熟練した医療専門家の確保にも限界があります。イノベーションの努力は、非侵襲的診断ツール、新規薬剤製剤、女性のライフサイクルにわたる多面的なニーズに対応する包括的医療プラットフォームの開発に軸足を置くべきです。継続的な教育と啓発キャンペーンは、より広範な医療改革に女性の健康を含めることと同様に極めて重要です。市場は、科学、ポリシー、消費者行動の組み合わせによって動かされるダイナミックなものであり、成功するのは、最先端の研究を活用し、戦略的提携を結び、規制環境を乗りこなしながら進化する消費者の期待に適応できる企業であると考えられます。

市場力学：急速に進化する女性の健康治療市場の主要市場洞察を公開

女性の健康治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 女性の慢性的な健康状態の増加
  • 女性の健康と性的健康の向上を目指す政府の取り組み
  • 不妊症や更年期障害の治療の増加
• 市場抑制要因
  • 健康保険未加入による治療費の高騰
• 市場機会
  • デジタル個別化医療とフェムテックの台頭
  • 女性特有の未病を治療するための細胞・遺伝子治療の進歩
• 市場課題
  • 様々な治療法の副作用に関する懸念

ポーターのファイブフォース：女性の健康治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：女性の健康治療市場における外部からの影響の把握

外部マクロ環境要因は、女性の健康治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：女性の健康治療市場における競合情勢の把握

女性の健康治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：女性の健康治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、女性の健康治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：女性の健康治療市場における成功への道筋を描く

女性の健康治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 女性における慢性疾患の発症率増加
    • 女性の健康と性的健康を改善するための政府の取り組み
    • 不妊症と更年期障害治療の増加
  • 抑制要因
    • 健康保険がないため治療費が高額
  • 機会
    • デジタルパーソナライズ医療とフェムテックの台頭
    • 女性特有の疾患を治療するための細胞・遺伝子治療の進歩
  • 課題
    • さまざまな治療法の副作用に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 女性の健康治療市場：タイプ別

• イントロダクション
• 感染
• 腫瘍
  • 子宮頸がん
  • 卵巣がん
  • 子宮がん
• 妊娠
• 膣がんと外陰がん

第7章 女性の健康治療市場：流通チャネル別

• イントロダクション
• ドラッグストアと薬局
• 病院薬局
• オンライン薬局

第8章 南北アメリカの女性の健康治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の女性の健康治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの女性の健康治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Agile Therapeutics Inc.
• Amgen Inc.
• Bayer AG
• F. Hoffmann La Roche Ltd.
• Ferring B.V.
• GLS Pharma Pvt. Ltd.
• Mithra Pharmaceuticals SA.
• Novartis AG
• Novo Nordisk AS
• ObsEva SA
• Pfizer Inc.
• Radius Health Inc.
• Sanofi SA

LIST OF FIGURES

• FIGURE 1. WOMEN'S HEALTH THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. WOMEN'S HEALTH THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. WOMEN'S HEALTH THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. WOMEN'S HEALTH THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. WOMEN'S HEALTH THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VAGINAL & VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. CANADA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. CANADA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CHINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. INDIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. ITALY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. ITALY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. POLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. POLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. QATAR WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. QATAR WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. WOMEN'S HEALTH THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. WOMEN'S HEALTH THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Women's Health Therapeutics Market was valued at USD 65.49 billion in 2023, expected to reach USD 72.21 billion in 2024, and is projected to grow at a CAGR of 10.74%, to USD 133.82 billion by 2030.

The Women's Health Therapeutics market focuses on treatments addressing conditions and diseases unique to or more prevalent in women, encompassing reproductive health, menopause, osteoporosis, and certain autoimmune and cardiovascular diseases. The necessity of this market lies in the demographic's specific physiological needs, ensuring better health outcomes tailored to women's unique biological makeup. Applications within the market include pharmaceuticals, biologics, devices, and diagnostics, with end-use scope covering hospitals, clinics, retail pharmacies, and online platforms. Key growth drivers include rising awareness of women's health issues, increased healthcare expenditure, advancements in biotechnology, and supportive governmental policies promoting women's health initiatives. Opportunities abound in personalized medicine and the integration of digital health technologies like wearable devices and telemedicine, which offer personalized monitoring and treatment. Companies can capitalize on these opportunities by investing in R&D and partnerships with tech firms, healthcare providers, and health advocacy groups. However, market growth faces challenges such as high research costs, regulatory barriers, and cultural stigma around women-specific health issues in certain regions, affecting both market penetration and acceptance. Additionally, there are limitations in reimbursement policies and the availability of skilled healthcare professionals in some areas. Innovation efforts should pivot towards developing non-invasive diagnostic tools, novel drug formulations, and comprehensive healthcare platforms that address multifaceted needs across a woman's life cycle. Continuous education and awareness campaigns are crucial, as is the inclusion of women's health in broader healthcare reforms. The market is dynamic, driven by a combination of science, policy, and consumer behavior, where successful players will be those who can leverage cutting-edge research, form strategic alliances, and adapt to evolving consumer expectations while navigating regulatory environments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Women's Health Therapeutics Market

The Women's Health Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of chronic health conditions among women
  • Government initiatives to improve women's health and sexual wellness
  • Increasing prevalence of infertility and menopausal treatments
• Market Restraints
  • High cost of treatment due to lack of health insurance
• Market Opportunities
  • Rise in digital personalized healthcare and femtech
  • Advances in cell and gene therapy to treat underserved female-specific conditions
• Market Challenges
  • Concerns related to side-effects of various therapies

Porter's Five Forces: A Strategic Tool for Navigating the Women's Health Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Women's Health Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Women's Health Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Women's Health Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Women's Health Therapeutics Market

A detailed market share analysis in the Women's Health Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Women's Health Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Women's Health Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Women's Health Therapeutics Market

A strategic analysis of the Women's Health Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Women's Health Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Agile Therapeutics Inc., Amgen Inc., Bayer AG, F. Hoffmann La Roche Ltd., Ferring B.V., GLS Pharma Pvt. Ltd., Mithra Pharmaceuticals SA., Novartis AG, Novo Nordisk AS, ObsEva SA, Pfizer Inc., Radius Health Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Women's Health Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Infection, Oncology, Pregnancy, and Vaginal & Vulvar Cancer. The Oncology is further studied across Cervical Cancer, Ovarian Cancer, and Uterine Cancer.
• Based on Distribution Channel, market is studied across Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of chronic health conditions among women
    • 5.1.1.2. Government initiatives to improve women's health and sexual wellness
    • 5.1.1.3. Increasing prevalence of infertility and menopausal treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment due to lack of health insurance
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in digital personalized healthcare and femtech
    • 5.1.3.2. Advances in cell and gene therapy to treat underserved female-specific conditions
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns related to side-effects of various therapies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Women's Health Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Infection
• 6.3. Oncology
  • 6.3.1. Cervical Cancer
  • 6.3.2. Ovarian Cancer
  • 6.3.3. Uterine Cancer
• 6.4. Pregnancy
• 6.5. Vaginal & Vulvar Cancer

7. Women's Health Therapeutics Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Drug Stores & Retail Pharmacies
• 7.3. Hospital Pharmacies
• 7.4. Online Pharmacies

8. Americas Women's Health Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Women's Health Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Women's Health Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Agile Therapeutics Inc.
• 4. Amgen Inc.
• 5. Bayer AG
• 6. F. Hoffmann La Roche Ltd.
• 7. Ferring B.V.
• 8. GLS Pharma Pvt. Ltd.
• 9. Mithra Pharmaceuticals SA.
• 10. Novartis AG
• 11. Novo Nordisk AS
• 12. ObsEva SA
• 13. Pfizer Inc.
• 14. Radius Health Inc.
• 15. Sanofi SA